FOR ADULTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA

LIVE PROGRESSION FREE

In 2 different trials, more people lived progression free when treated with sarclisa given with other therapies

Living progression free means living without your multiple myeloma getting worse.
Trial 1: At an average follow-up of 20.7 months, 74% (133 of 179 people) lived progression free with sarclisa + Kyprolis® (carfilzomib) and dexamethasone (Kd) vs 59% (73 of 123 people) treated with Kd alone. Trial 2: At an average follow-up of 11.6 months, 53% (81 of 154 people) lived progression free with SARCLISA + Pomalyst® (pomalidomide) and dexamethasone (Pd) vs 42% (64 of 153 people) treated with Pd alone.

sarclisa was proven
in two Phase 3 trials.

See the results

sarclisa is a targeted
immunotherapy that works
together with your
immune system.

See how it works

CareASSIST helps eligible patients with access and support for sarclisa.

Find out more